On July 12, the 43rd National Pharmaceutical Industry Information Conference 2026, organized by the China Pharmaceutical Industry Information Center, opened in Beijing. The conference announced the "Top 100 Enterprises in China's Pharmaceutical Industry Revenue in 2025". Haisco Pharmaceutical Group ranked 69th, up from 88th last year, a 19-rank improvement.

Data source:2025 “China Pharmaceutical Industry Statistical Annual Report”

2025 is a critical year for concluding the "14th Five-Year Plan" and planning for the "15th Five-Year Plan". With the slowdown in domestic market growth, intensified industry competition, along with deep adjustments in the global supply chain and increasing uncertainties due to geopolitical conflicts, China’s pharmaceutical industry is operating under pressure. It is going through the pain of structural adjustment and energy transformation, and pharmaceutical companies are also facing unprecedented challenges.

The top 100 pharmaceutical companies in China are benchmarks and a pillar of industry development.In 2025, Chinese pharmaceutical industrial enterprises remain at the forefront, with varying growth strategies.The core driving forces focus on three strategic directions: building differentiated barriers through innovation and iteration, expanding growth opportunities through global deployment, and enhancing risk resistance through industrial integration.By maintaining long-term strategic focus and continuous investment, the top 100 enterprises have established a diverse and resilient growth system under the overall challenging environment of the industry, providing a practical example for the transformation of new and old energy in the entire sector.

Adhering to innovation and internationalization strategies, Hisicor Pharmaceutical Group continuously improves the research and development, clinical, and production coordination system, and has established operations across the country.5 modern production bases and over 30 production lines to accelerate the industrialization of innovation achievements. The group has formed a R&D team of more than a thousand people, with R&D investment exceeding 1 billion yuan for several years. Focusing on key therapeutic areas such as anesthesia and analgesia, chronic disease metabolism, digestive liver diseases, respiratory system, autoimmunity, and tumors, 26 innovative drug projects of category 1 have been developed. A phased R&D system covering pre-clinical research, Phase I, II, and III clinical trials has been established. Four innovative drugs of category 1 have been approved for market release, and all are included in the national basic medical insurance catalog. Among them, cyclopropanil injection, a innovative intravenous anesthetic with independent intellectual property rights in China, was approved by the US Food and Drug Administration (FDA) at the end of May this year, marking a new breakthrough for domestic innovative intravenous anesthetics to enter the US market.

At the same time, Hisicor is accelerating its internationalization process and has established partnerships with AbbVie and Eli Lilly.Many international pharmaceutical companies such as Nuvectis are engaging in collaborative research and development of innovative drugs and overseas licensing, covering various key areas including oncology and autoimmune diseases. This indicates that China's capabilities in innovative drug research and development are being recognized in the international market.

The National Pharmaceutical Industry Information Annual Conference is an annual event in the pharmaceutical industry organized by the China Pharmaceutical Industry Information Center. It is regarded as a barometer of the development of the pharmaceutical industry.

ChapterThe "Top 100 Chinese Pharmaceutical Industries Companies" released at the 43rd National Pharmaceutical Industry Information Conference is based on the top 100 companies in China's pharmaceutical industry revenue in 2025. It is compiled mainly from the business income listed in the "China Pharmaceutical Industry Statistical Annual Report." This ranking represents the most authoritative and influential comprehensive strength of enterprises in the pharmaceutical industry in China, aiming to set a benchmark for the industry.